Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Cancer treatments Stories

2013-01-29 23:03:21

One of the California's most modern Cancer Centers, El Portal Comprehensive Cancer is moving to a much-anticipated new location in Merced. Their new office features a plethora of innovative, highly-effective treatments including stereotactic radiotherapy and high dose rate brachytherapy. Merced, California (PRWEB) January 29, 2013 El Portal Comprehensive Cancer is moving to a much-anticipated new location in Merced that will better enable them to help members of the community who are...

2013-01-29 08:30:41

BETHESDA, Md., Jan. 29, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for cancer, announced today that Dr. Marnix Bosch, the Company's Chief Technical Officer, will be presenting at the Phacilitate Cell And Gene Therapy Forum 2013, today at 3:30 pm in a session entitled Clinical Development Updates: Oncology. The conference is being held at the Grand Hyatt Hotel at 10(th) and H...

2013-01-25 12:25:40

VANCOUVER, British Columbia and MENLO PARK, Calif., Jan. 25, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: BRRY) ("DelMar") today announced the successful acquisition (the "Acquisition"), through a share exchange agreement, of all of the outstanding shares of Del Mar Pharmaceuticals (BC) Ltd., a clinical and commercial stage drug development company with a focus on the treatment of cancer. Concurrent with the Acquisition, DelMar completed the first closing in a private placement...

2013-01-24 13:44:54

With a desire to inhibit metastasis, Cornell biomedical engineers have found the natural switch between the body's inflammatory response and how malignant breast cancer cells use the bloodstream to spread. (PLOS ONE, Jan. 23, 2013) Pro-inflammatory signaling molecules in blood called cytokines constitute a "switch" that induces the mechanism by which breast cancer cells "roll" and adhere to the blood vessel surface. The cancer cells eventually stick to the vessel and infiltrate it. The...

2013-01-23 08:28:57

REDWOOD CITY, Calif., Jan. 23, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from three studies of the Oncotype DX(®) Colon Cancer test at the 2013 Gastrointestinal (GI) Cancers Symposium, including new data demonstrating that Recurrence Score(®) (RS) results changed treatment recommendations in 45 percent of the enrolled stage II colon cancer patients. Presentations also include positive findings from a second health economics analysis suggesting...

2013-01-22 12:27:30

TSX Venture: QPT EDMONTON, Jan. 22, 2013 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has achieved 50% accrual having enrolled the 40(th) patient in its ongoing 80 patient Phase II Oregovomab front-line chemo-immunotherapy clinical trial in Italy and the U.S. The objective of this study is to confirm that optimally dosed oregovomab in...

2013-01-17 12:26:38

SAN DIEGO, Jan. 17, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that Laszlo Radvanyi, Ph.D., an Associate Professor in the Department of Melanoma Medical Oncology Research at the University of Texas MD Anderson Cancer Center in Houston, has joined its Scientific Advisory Board. "I am excited to be a part of Aethlon's...

2013-01-17 08:25:55

SAN DIEGO, Jan. 17, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that Punit Dhillon, President and CEO, will present at the Noble Financial Capital Markets' Ninth Annual Equity Conference, at the Hard Rock Hotel in Hollywood, Florida, on Tuesday, January 22 at 12:30 PM Eastern Time. (Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO)...

2013-01-15 08:24:26

SAN DIEGO, Jan. 15, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) In 2012, researchers published the discovery that small particles known as exosomes are secreted by tumors to seed the creation and spread of cancer metastases. These same tumor-secreted exosomes have also been implicated in death of immune cells necessary to combat...

2013-01-15 07:17:10

SAN DIEGO, Jan. 15, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced the company's upcoming milestones for 2013 at the Biotech Showcase conference held January 7-9 in San Francisco, CA. (Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO) "2012 marked a critical year for OncoSec," said Punit Dhillon, President and CEO. "We launched three...